Iovance Biotherapeutics Stock Price. Everything You Need To Know About The Iovance Biotherapeutics Stock!
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 503 full-time employees. The company went IPO on 2008-06-20. The firm is focused on the development and commercialization of cell therapies as cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The company has developed a new, shorter manufacturing process for tumor infiltrating lymphocyte (TIL) known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. Its lead product candidates include lifileucel for metastatic melanoma and metastatic cervical cancer, as well as LN-145 for metastatic non-small cell lung cancer (NSCLC). In addition, the Company is investigating the combinations of TIL therapy with immune checkpoint inhibitors (ICIs) in metastatic melanoma, cervical cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC). The company is investigating peripheral blood lymphocyte (PBL) therapy for patients with refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Iovance Biotherapeutics Stock Price. Everything You Need To Know About The Iovance Biotherapeutics Stock! performance
- Employees 503
- Company HQ San Carlos
- Website https://www.iovance.com/
- IOVA Asset Type Common Stock
- IOVA Market Capitalization 3.3B
- Earnings Per Share -1.89
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Iovance Biotherapeutics is a stock that offers promising investment opportunities for retail investors in Malaysia, Thailand, Indonesia, and Vietnam. As a leading bio-pharmaceutical company, Iovance focuses on the development and commercialization of novel cancer immunotherapies to fight against various types of tumors. For investors in these countries who are interested in investing in Iovance Biotherapeutics, there are a few key steps to consider. First, it is essential to research and understand the company’s background, including their innovative pipeline of potential drugs. Next, investors should evaluate the market potential and existing competition associated with Iovance’s immunotherapies. It is crucial to keep track of the latest news and updates about the company’s clinical trials, partnerships, and regulatory approvals. To invest in Iovance Biotherapeutics, retail investors from Malaysia, Thailand, Indonesia, and Vietnam can utilize the services provided by Zorion, an investment platform that offers insights and recommendations specific to this stock. With Zorion, investors can access educational resources and informative articles to enhance their knowledge about Iovance and make informed investment decisions. By staying informed and utilizing the comprehensive resources available, investors from these countries can navigate the stock market effectively and potentially benefit from investing in Iovance Biotherapeutics.
